Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus

NCT03011008 · Unknown status

Last updated 2026-05-28

This clinical trial is testing whether adding the medication liraglutide to insulin treatment helps manage blood sugar levels in adults with autoimmune diabetes.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 20 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2017-01 · est. completion 2021-06

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT03011008 ↗

Description as written by the study sponsor.

The purpose of this study is to investigate the therapeutic effect of Liraglutide on autoimmune diabetes.

Treatments tested

Liraglutide Drug

Dose escalation of liraglutide starts from 0.6 mg up to 1.2 mg per day.
Insulin Drug

Receive insulin following clinician's instruction.

Main thing measured	Mean amplitude of glycemic excursions (MAGE)
Sponsor	Second Xiangya Hospital of Central South University
Conditions studied	Type 1 Diabetes Mellitus, Autoimmune Diabetes
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03011008 ↗